On October 11, 2024 EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, reported the company will be presenting two poster presentations at the upcoming 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2024) taking place in Houston, Texas, from November 6-10, 2024, at the George R. Brown Convention Center (Press release, EpimAb Biotherapeutics, OCT 11, 2024, View Source [SID1234648251]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters will feature: 1) preclinical results for a novel cMet x EGFR bispecific antibody-drug conjugate (ADC) and 2) development and preclinical data for an innovative NK cell engager platform. Details for the presentations are as follows:

cMet x EGFR ADC
Title: A differentiated cMet x EGFR bispecific antibody-drug conjugate demonstrated broad antitumor activity and promising safety profile in preclinical models
Presentation number: 1048
Presentation Date: Saturday, November 9, 2024
Presentation Time: Poster Viewing 12:15-1:45pm CST; Poster Reception 7:10-8:30pm CST (Exhibit Halls AB)

NK Cell Engager Platform
Title: The development of IL15v-NKCE: A cutting-edge NK cell engager platform for cancer treatment
Presentation number: 1078
Presentation Date: Saturday, November 9, 2024
Presentation Time: Poster Viewing 12:15-1:45pm CST; Poster Reception 7:10-8:30pm CST (Exhibit Halls AB)